Dr. Srinivasa Reddy Bonam is a
Senior Scientist at the Department of Applied Biology, CSIR-Indian Institute of
Chemical Sciences (IICT), Hyderabad, India. He completed his PhD studies in immunology
at the Academy of Scientific and Innovative Research (AcSIR) and has been
awarded the Raman Charpak Fellowship (RCF) by the CEFIPRA/IFCPAR/ and several other
honors. Under the guidance of Prof. Sylviane
Muller at the Molecular and Cellular Biology Institute, University of
Strasbourg, France (2018-2020), he worked on the “therapeutic strategies for
autoimmune diseases, including P140 [Lupuzor®—a 21-mer peptide acting against
systemic lupus erythematosus]. Later, he continued his postdoctoral research
on various aspects of immunology, including regulatory T cells (Tregs),
basophils, next-generation flu vaccines for the world and COVID-19
with Prof. Jagadeesh Bayry at the INSERM, Paris, France. He then moved to the University of Texas
Medical Branch (UTMB) in the Department of Microbiology and Immunology, where
he trained under Dr. Haitao Hu, and developed novel mRNA vaccines for emerging
infectious diseases, including COVID-19 and therapeutics. At present, he is a
Senior Scientist at CSIR-IICT, Hyderabad.
His current research focuses on the development of Vaccines and CAR-T
cell therapeutics. He has published 90 research and review papers and 7 book
chapters, and he has five patents to his credit. He serves as an associate editor and
editorial board member for various journals.
Dr. Srinivasa Reddy Bonam is a
Senior Scientist at the Department of Applied Biology, CSIR-Indian Institute of
Chemical Sciences (IICT), Hyderabad, India. He completed his PhD studies in immunology
at the Academy of Scientific and Innovative Research (AcSIR) and has been
awarded the Raman Charpak Fellowship (RCF) by the CEFIPRA/IFCPAR/ and several other
honors. Under the guidance of Prof. Sylviane
Muller at the Molecular and Cellular Biology Institute, University of
Strasbourg, France (2018-2020), he worked on the “therapeutic strategies for
autoimmune diseases, including P140 [Lupuzor®—a 21-mer peptide acting against
systemic lupus erythematosus]. Later, he continued his postdoctoral research
on various aspects of immunology, including regulatory T cells (Tregs),
basophils, next-generation flu vaccines for the world and COVID-19
with Prof. Jagadeesh Bayry at the INSERM, Paris, France. He then moved to the University of Texas
Medical Branch (UTMB) in the Department of Microbiology and Immunology, where
he trained under Dr. Haitao Hu, and developed novel mRNA vaccines for emerging
infectious diseases, including COVID-19 and therapeutics. At present, he is a
Senior Scientist at CSIR-IICT, Hyderabad.
His current research focuses on the development of Vaccines and CAR-T
cell therapeutics. He has published 90 research and review papers and 7 book
chapters, and he has five patents to his credit. He serves as an associate editor and
editorial board member for various journals.